Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert "Cold" Tumors to "Hot" Tumors

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jul 13

PMID 39000314

Authors

Liucui Yang

Qingyi Hu

Tao Huang

Affiliations

Soon will be listed here.

Abstract

Breast cancer characterized as "cold tumors" exhibit low levels of immune cell infiltration, which limits the efficacy of conventional immunotherapy. Recent studies have focused on strategies using nanotechnology combined with tumor microenvironment modulation to transform "cold tumors" into "hot tumors". This approach involves the use of functionalized nanoparticles that target and modify the tumor microenvironment to promote the infiltration and activation of antitumor immune cells. By delivering immune activators or blocking immunosuppressive signals, these nanoparticles activate otherwise dormant immune responses, enhancing tumor immunogenicity and the therapeutic response. These strategies not only promise to increase the response rate of breast cancer patients to existing immunotherapies but also may pave new therapeutic avenues, providing a new direction for the immunotherapy of breast cancer.

Citing Articles

Real‑world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer.

Qian X, Tao Y, Chen H, Li X, Wang Y, Xu X Oncol Lett. 2024; 29(1):29.

PMID: 39512498 PMC: 11542155. DOI: 10.3892/ol.2024.14775.

References

Erra Diaz F, Dantas E, Geffner J . Unravelling the Interplay between Extracellular Acidosis and Immune Cells. Mediators Inflamm. 2019; 2018:1218297. PMC: 6332927. DOI: 10.1155/2018/1218297. View

Reeves A, Vinogradov S, Morrissey P, Chernin M, Ahmed M . Curcumin-encapsulating Nanogels as an Effective Anticancer Formulation for Intracellular Uptake. Mol Cell Pharmacol. 2016; 7(3):25-40. PMC: 4770584. DOI: 10.4255/mcpharmacol.15.04. View

Cun X, Chen J, Li M, He X, Tang X, Guo R . Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle. ACS Appl Mater Interfaces. 2019; 11(43):39545-39559. DOI: 10.1021/acsami.9b13957. View

Fu W, Lei C, Yu Y, Liu S, Li T, Lin F . EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency. Clin Cancer Res. 2019; 25(9):2835-2847. DOI: 10.1158/1078-0432.CCR-18-2732. View

van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I, Le Cabec V . Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J Immunol. 2009; 184(2):1049-61. DOI: 10.4049/jimmunol.0902223. View

Hong R, Zhou Y, Tian X, Wang L, Wu X . Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1breast cancer via enhancing immune cells activity. Int Immunopharmacol. 2017; 54:118-124. DOI: 10.1016/j.intimp.2017.10.008. View

Sharma P, Lopez-Tarruella S, Garcia-Saenz J, Khan Q, Gomez H, Prat A . Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res. 2018; 24(23):5820-5829. PMC: 6279513. DOI: 10.1158/1078-0432.CCR-18-0585. View

Zhang B, Shi J, Shi X, Xu X, Gao L, Li S . Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat. 2024; 74:101068. DOI: 10.1016/j.drup.2024.101068. View

Cheng Y, Zou J, He M, Hou X, Wang H, Xu J . Spatiotemporally controlled Pseudomonas exotoxin transgene system combined with multifunctional nanoparticles for breast cancer antimetastatic therapy. J Control Release. 2023; 367:167-183. DOI: 10.1016/j.jconrel.2023.08.011. View

10.

Khlebtsov N, Dykman L . Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2010; 40(3):1647-71. DOI: 10.1039/c0cs00018c. View

11.

Strauss J, Gatti-Mays M, Cho B, Hill A, Salas S, McClay E . Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020; 8(2). PMC: 7745517. DOI: 10.1136/jitc-2020-001395. View

12.

Tao J, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N . Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014; 7(318):ra29. PMC: 4283215. DOI: 10.1126/scisignal.2005125. View

13.

Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J . Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018; 128(11):5137-5149. PMC: 6205399. DOI: 10.1172/JCI96268. View

14.

Geyer F, Pareja F, Weigelt B, Rakha E, Ellis I, Schnitt S . The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. Am J Pathol. 2017; 187(10):2139-2151. PMC: 5809519. DOI: 10.1016/j.ajpath.2017.03.016. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Reddy S, Swartz M, Hubbell J . Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006; 27(12):573-9. DOI: 10.1016/j.it.2006.10.005. View

17.

Liu H, Bai L, Huang L, Ning N, Li L, Li Y . Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. J Immunother Cancer. 2021; 9(10). PMC: 8488747. DOI: 10.1136/jitc-2021-003468. View

18.

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell H, Ibrahim-Hashim A . Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5):1524-35. PMC: 3594450. DOI: 10.1158/0008-5472.CAN-12-2796. View

19.

Oh S, Li M . TGF-β: guardian of T cell function. J Immunol. 2013; 191(8):3973-9. PMC: 3856438. DOI: 10.4049/jimmunol.1301843. View

20.

Song Y, Tang C, Yin C . Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials. 2018; 185:117-132. DOI: 10.1016/j.biomaterials.2018.09.017. View